{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:14:28Z","timestamp":1755598468275,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Markman\u2019s desensitisation protocol allows successful retreatment of patients who have had significant paclitaxel hypersensitivity reactions. We aimed to reduce the risk and severity of paclitaxel hypersensitivity reactions by introducing this protocol as primary prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We evaluated all patients with a gynaecological malignancy receiving paclitaxel before (December 2018 to September 2019) and after (October 2019 to July 2020) the implementation of a modified Markman\u2019s desensitisation protocol. The pre-implementation group received paclitaxel over a gradually up-titrated rate from 60 to 180\u00a0ml\/h. The post-implementation group received paclitaxel via 3 fixed-dose infusion bags in the first 2 cycles. Rates and severity of paclitaxel hypersensitivity reactions were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 426 paclitaxel infusions were administered to 78 patients. The median age was 64\u00a0years (range 34\u201381), and the most common diagnosis was ovarian, fallopian tube and primary peritoneal cancer (67%, <jats:italic>n<\/jats:italic>\u2009=\u200952\/78). Paclitaxel hypersensitivity reaction rates were similar in the pre-implementation (8%, <jats:italic>n<\/jats:italic>\u2009=\u200916\/195) and post-implementation groups (9%, <jats:italic>n<\/jats:italic>\u2009=\u200920\/231; <jats:italic>p<\/jats:italic>\u2009=\u20090.87). Most paclitaxel hypersensitivity reactions occurred within 30\u00a0min (pre- vs. post-implementation, 88% [<jats:italic>n<\/jats:italic>\u2009=\u200914\/16] vs. 75% [<jats:italic>n<\/jats:italic>\u2009=\u200915\/20]; <jats:italic>p<\/jats:italic>\u2009=\u20090.45) and were grade 2 in severity (pre- vs. post-implementation, 81% [<jats:italic>n<\/jats:italic>\u2009=\u200913\/16] vs. 75% [<jats:italic>n<\/jats:italic>\u2009=\u200915\/20]; <jats:italic>p<\/jats:italic>\u2009=\u20090.37). There was one grade 3 paclitaxel hypersensitivity reaction in the pre-implementation group. All patients were successfully rechallenged in the post-implementation group compared to 81% (<jats:italic>n<\/jats:italic>\u2009=\u200913\/16) in the pre-implementation group (<jats:italic>p<\/jats:italic>\u2009=\u20090.43).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The modified Markman\u2019s desensitisation protocol as primary prophylaxis did not reduce the rate or severity of paclitaxel hypersensitivity reactions, although all patients could be successfully rechallenged.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08460-z","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T19:01:53Z","timestamp":1713380513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rates of paclitaxel hypersensitivity reactions using a\u00a0modified Markman\u2019s infusion protocol as primary prophylaxis"],"prefix":"10.1007","volume":"32","author":[{"given":"Rebecca","family":"Symons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Tam","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeh Chen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"issue":"3","key":"8460_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12032-007-9030-2","volume":"25","author":"J Zidan","year":"2008","unstructured":"Zidan J, Hussein O, Abzah A, Tamam S, Farraj Z, Friedman E (2008) Oral premedication for the prevention of hypersensitivity reactions to paclitaxel. Med Oncol 25(3):274\u2013278","journal-title":"Med Oncol"},{"key":"8460_CR2","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00520-011-1303-9","volume":"20","author":"MJ Berger","year":"2012","unstructured":"Berger MJ, Dulles LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL (2012) Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion reaction. Support Care Cancer 20:1991\u20131997","journal-title":"Support Care Cancer"},{"issue":"4","key":"8460_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3747\/co.21.1966","volume":"21","author":"J Boulanger","year":"2014","unstructured":"Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K, the Comite de l\u2019evolution des pratiquesenoncologie (2014) Management of hypersensitivity to platinum- and taxane-based chemotherapy: CEPO review and clinical recommendations. Curr Oncol 21(4):630\u2013641","journal-title":"Curr Oncol"},{"issue":"6","key":"8460_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11882-021-01014-x","volume":"21","author":"J Caiado","year":"2021","unstructured":"Caiado J, Castells MC (2021) Drug desensitizations for chemotherapy: safety and efficacy in preventing anaphylaxis. Curr Allergy Asthma Rep 21(6):1\u201313","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"8460_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40259-013-0066-x","volume":"28","author":"V Mezzano","year":"2014","unstructured":"Mezzano V, Giavina-Bianchi P, Picard M, Caiado J, Castells M (2014) Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. BioDrugs 28(2):133\u2013144","journal-title":"BioDrugs"},{"issue":"1","key":"8460_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00280-017-3332-7","volume":"80","author":"T Aoyama","year":"2017","unstructured":"Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Soyama H, Kato K, Ishibashi H, Iwahashi H, Nakatsuka M, Yajima I, Shimizu Y (2017) Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy? Cancer Chemother Pharmacol 80(1):65\u201369","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"8460_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2217\/pgs.10.32","volume":"11","author":"C Rodr\u00edguez-Antona","year":"2010","unstructured":"Rodr\u00edguez-Antona C (2010) Pharmacogenomics of paclitaxel. Pharmacogenomics 11(5):621\u2013623","journal-title":"Pharmacogenomics"},{"issue":"32","key":"8460_CR8","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1200\/JCO.21.01200","volume":"39","author":"OM Lansinger","year":"2021","unstructured":"Lansinger OM, Biedermann S, He Z, Colevas AD (2021) Do steroids matter? A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions. J Clin Oncol 39(32):3583\u2013590","journal-title":"J Clin Oncol"},{"issue":"1","key":"8460_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markman","year":"2000","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18(1):102\u2013102","journal-title":"J Clin Oncol"},{"key":"8460_CR10","unstructured":"EviQ protocol ID 3264 v.3: Premedication for prophylaxis of taxane hypersensitivity reactions (infusion related reactions and anaphylaxis). https:\/\/www.eviq.org.au\/clinical-resources\/side-effect-and-toxicity-management\/immunological\/3264-premedication-for-prophylaxis-of-taxane-hyper. Accessed 5th Feb 2024"},{"key":"8460_CR11","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Cancer Institue. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed: 24th April 2023"},{"issue":"2","key":"8460_CR12","first-page":"46","volume":"11","author":"E Dewaele","year":"2017","unstructured":"Dewaele E, Verschueren C, Specenier P (2017) Premedication strategy for paclitaxel, still an unsolved question after 30 years. Belg J Med Oncol-Amsterdam, 2007, Currens 11(2):46\u201355","journal-title":"Belg J Med Oncol-Amsterdam, 2007, Currens"},{"issue":"7","key":"8460_CR13","doi-asserted-by":"publisher","first-page":"19236","DOI":"10.1097\/IGC.0b013e31829f1799","volume":"23","author":"SM O\u2019Cathail","year":"2013","unstructured":"O\u2019Cathail SM, Shaboodien R, Mahmoud S, Carty K, O\u2019Sullivan P, Blagden S, Kwon JS, Agarwal R (2013) Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies. Int J Gynecolo Cancer 23(7):19236","journal-title":"Int J Gynecolo Cancer"},{"issue":"7","key":"8460_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/1078155216664203","volume":"23","author":"A Yenilmez","year":"2017","unstructured":"Yenilmez A, Hood AP, Nguyen LH, Merl MY (2017) Paclitaxel pre-medication: a comparison of two steroid pre-medication protocols. J Oncol Pharm Pract 23(7):491\u2013495","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"8460_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00130404-200207000-00010","volume":"8","author":"JA Krieger","year":"2002","unstructured":"Krieger JA, Stanford BL, Ballard EE, Rabinowitz I (2002) Implementation and results of a test dose program with taxanes. J Cancer 8(4):337\u2013341","journal-title":"J Cancer"},{"issue":"3","key":"8460_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00130404-200605000-00013","volume":"12","author":"A Henry","year":"2006","unstructured":"Henry A, Charpiat B, Perol M, Vial T, de Saint Hilaire PJ, Descotes J (2006) Paclitaxel hypersensitivity reactions: assessment of the utility of a test-dose program. J Cancer 12(3):237\u2013245","journal-title":"J Cancer"},{"issue":"3","key":"8460_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12016-021-08877-y","volume":"62","author":"LR Tsao","year":"2021","unstructured":"Tsao LR, Young FD, Otani IM, Castells MC (2021) Hypersensitivity reactions to platinum agents and taxanes. Clin Rev Allergy Immunol 62(3):432\u2013448","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"8460_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ajco.12495","volume":"12","author":"M Yanaranop","year":"2016","unstructured":"Yanaranop M, Chaithongwongwatthana S (2016) Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: a double-blind randomized controlled trial. Asia-Pac J Clin Oncol 12(3):289\u2013299","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"2","key":"8460_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/CRST.CRST_6_19","volume":"1","author":"V Noronha","year":"2018","unstructured":"Noronha V, Enting D, Thippeswamy R, Joshi A, Patil VM, Prabhash K (2018) Hypersensitivity reactions to paclitaxel with a modified dexamethasone intravenous premedication regimen. Cancer Res Stat Treat 1(2):78","journal-title":"Cancer Res Stat Treat"},{"issue":"6","key":"8460_CR20","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1200\/OP.22.00845","volume":"19","author":"DM Lynch","year":"2023","unstructured":"Lynch DM, Menon S, Mazzola E, Costa J, Jabaley T (2023) A three-step taxane titration protocol decreases hypersensitivity reactions during first and second exposures. JCO Oncol Pract 19(6):e942\u2013e950","journal-title":"JCO Oncol Pract"},{"key":"8460_CR21","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/S0090-8258(21)00865-9","volume":"162","author":"E Ferrigni","year":"2021","unstructured":"Ferrigni E, Grate L, Herzog T, Billingsley C, Jackson A (2021) Comparison of incidence of hypersensitivity reactions of paclitaxel infusions with titrated versus non-titrated infusions. Gynecol Oncol 162:S117\u2013S118","journal-title":"Gynecol Oncol"},{"issue":"8","key":"8460_CR22","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1007\/s00520-021-05991-7","volume":"29","author":"K Nymberg","year":"2021","unstructured":"Nymberg K, Folan S, Berger M, Li J, Zanath K, VanDeusen J, Vargo C (2021) Comparison of subsequent infusion hypersensitivity reactions to paclitaxel using two different infusion strategies. Support Care Cancer 29(8):4423\u20134429","journal-title":"Support Care Cancer"},{"issue":"8","key":"8460_CR23","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7(8):1401\u20131053","journal-title":"Expert Opin Pharmacother"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08460-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08460-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08460-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:13:22Z","timestamp":1715591602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08460-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["8460"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08460-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"14 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the South Eastern Sydney Local Health District HREC (2023\/ETH01301). Consent waiver was approved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"YCL has received honoraria from GSK and AstraZeneca; and grants from BeiGene, outside the submitted work. MF has received consulting fees from AstraZeneca, GSK, Novartis and INCYCLIX as well as honoraria from AstraZeneca, GSK, MSD and Beigene, outside of the submitted work. RS, FH, KTB, and JD have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}